Active ingredients: lenvatinib
What it is used for
LENVIMA is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine refractory differentiated thyroid cancer. LENVIMA is indicated in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma whose disease has progressed following one prior vascular endothelial growth factor targeted therapy.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Oral
- Store below 30 degrees Celsius
- Lifetime is 48 Months.
Always read the label. If symptoms persist see your healthcare professional.
The 10mg capsule is a yellow body and a yellowish-red cap, marked in black ink with [lunate epsilon symbol] on the cap and LENV 10mg on the body
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient lenvatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf)